Study on Pharmacokinetics and Bioequivalence of Azithromycin Dispersible Tablets in Healthy Volunteers
Yuqing Xiong
Abstract
Yuqing Xiong
Abstract
OBJETIVE To study the pharmacokinetics and bioequivalence of azithromycin dispersible tablets in healthy volunteers.METHODS A single oral dose of 500 mg test or reference formulations was given to 20 male healthy volunteers in a randomized cross-over design.The concentration of azithromycin in plasma was determined by HPLC-MS.Pharmacokinetic parameters and relative bioavailability were calculated by DAS 2.0 software.RESULTS The main pharmacokinetic parameters of test and reference azithromycin were as the followings:AUC0-168(8.98±1.74) μg·h·mL-1 and(8.75±1.60) μg·h·mL-1;Cmax(0.81±0.14) μg·mL-1 and(0.80±0.14) μg·h·mL-1;t1/2(48.16±11.10) h and(51.1±7.60) h;Tmax(1.80±0.86) h and(1.82±0.92) h.The relative bioavailability of test to reference preparation was(103.4±20.2)%.CONCLUSION The test and reference formulations were bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJETIVE To study the pharmacokinetics and bioequivalence of azithromycin dispersible tablets in healthy volunteers.METHODS A single oral dose of 500 mg test or reference formulations was given to 20 male healthy volunteers in a randomized cross-over design.The concentration of azithromycin in plasma was determined by HPLC-MS.Pharmacokinetic parameters and relative bioavailability were calculated by DAS 2.0 software.RESULTS The main pharmacokinetic parameters of test and reference azithromycin were as the followings:AUC0-168(8.98±1.74) μg·h·mL-1 and(8.75±1.60) μg·h·mL-1;Cmax(0.81±0.14) μg·mL-1 and(0.80±0.14) μg·h·mL-1;t1/2(48.16±11.10) h and(51.1±7.60) h;Tmax(1.80±0.86) h and(1.82±0.92) h.The relative bioavailability of test to reference preparation was(103.4±20.2)%.CONCLUSION The test and reference formulations were bioequivalent.
Key concepts: Bioequivalence, Azithromycin, Pharmacokinetics, Bioavailability, Cmax, Pharmacology, Medicine, Plasma concentration